Replies to post #453464 on Anavex Life Sciences Corp (AVXL)

[crescentmotor]

The prize is the US FDA which we have NEVER heard DIRECT feedback on.

Fifteen months after getting top line data from a "successful" late stage trial in AD, and there has been almost stone cold silence about a path forward with the FDA except for the drumbeat of a promised peer review article that is not necessary for regulatory approval. This saga failed the smell test a long time ago. Missling is known for the bad/unreliable forward-looking guidance he gives investors but in the case of FDA approval possibilities for 2-73 in AD, he gives us absolutely nothing. At first, it seemed like Missling's priority goal of the $100 million Rett voucher was driving things, but after the EXCELLENCE trial failure, that has all evaporated.